Current Treatment Options in Neurology

, Volume 15, Issue 3, pp 281–288

Treatment Options in Newly Diagnosed Glioblastoma

  • Eudocia Q. Lee
  • Lakshmi Nayak
  • Patrick Y. Wen
  • David A. Reardon
NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

DOI: 10.1007/s11940-013-0226-9

Cite this article as:
Lee, E.Q., Nayak, L., Wen, P.Y. et al. Curr Treat Options Neurol (2013) 15: 281. doi:10.1007/s11940-013-0226-9

Opinion statement

Regardless of MGMT status, standard of care for a patient with newly diagnosed glioblastoma (GBM), age ≤70 years, and adequate functional status is radiation and concurrent temozolomide followed by adjuvant temozolomide. For elderly patients, recent studies have suggested that standard radiation, hypofractionated radiation, or single agent temozolomide are acceptable treatment options. Randomized phase III studies of bevacizumab in combination with radiation and temozolomide for newly diagnosed GBM have completed accrual. Preliminary results reveal a clear progression-free survival benefit. Overall survival appears unchanged although follow-up has not fully matured and cross-over to bevacizumab upon progression among control patients may limit definitive conclusions. Although bevacizumab in the upfront setting may be considered for a subset of patients, it should not be used routinely in newly diagnosed patients until final results are available. Clinical trials evaluating promising therapeutics given in combination with standard temozolomide chemoradiation are critically needed.

Keywords

GlioblastomaTemozolomideRadiationBevacizumabTreatmentNewly diagnosedCarmustine polymer wafers

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Eudocia Q. Lee
    • 1
  • Lakshmi Nayak
    • 1
  • Patrick Y. Wen
    • 1
  • David A. Reardon
    • 1
  1. 1.Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer CenterBostonUSA